Spring 2025 funding cycle: Applications available until Monday, March 3.
- Call opens: Thursday, January 30, 2025
- Deadline: Monday March 3, 2025 (2:00 pm PST)
- Funding results: Available before end of May 2025
Amount available: $50,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The CFAR Mentored Scientist Award (our primary award program) is a mentoring and training grant targeted toward early stage (either at a senior stage of clinical or postdoctoral training or junior faculty) investigators at UCSF or affiliated partner institutes in the conduct of an HIV research project. These awards are designed to acquire preliminary data and research skills to prepare investigators for a future grant effort. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project.
Designation of Mentor
All Mentored award applications from individuals at the Assistant Professor level or below require an HIV research mentor. Mentors can, but are not required to, have supervisory authority over the applicant. CFAR requires your research mentor’s support to advise and guide the research portion of your application before submitting it to RAP.
Of high interest to CFAR are investigations ranging from basic pathogenesis to clinical outcomes in the research areas of HIV/aging and inflammation, latency, cure, vaccines, co-infections, HIV in women, implementation science, and research related to HIV-infected and HIV-impacted Bay Area populations. Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
The award amount is $50,000 in direct costs for one year.
CFAR requests that applicants review the NIAID HIV Language Guide as they prepare their proposals so that they can follow best practices on language for communicating respectfully about HIV and related topics, including the use of person-first, non-stigmatizing language. Please contact us if you have any questions about this request.
For more detailed information about this RFA, please see the RAP Portal.
To see examples of previously funded projects, see the list below.
Mentored Science Awardees
128 Awards
-
Modulating Interleukin-2-Inducible T-cell Kinase (ITK) to Target HIV Persistence
Modulating Interleukin-2-Inducible T-cell Kinase (ITK) to Target HIV Persistence
Abstract
Inducible T-cell kinase (ITK) belongs to the Tec family of tyrosine kinases, and is expressed in mast cells and T lymphocytes. ITK functions downstream of the T-cell receptor (TCR) and regulates T-cell development, activation and differentiation. The role of ITK signaling in HIV persistence is yet unknown. In this proposal we aim to determine the impact of ITK on?HIV latency reversal and infected cell proliferation in primary CD4+?T cells and cell lines. In addition, we propose to investigate mechanisms regulating establishment of latency by regulating activation status of CD4+T cells.
-
Systematic testing for HIV and tuberculosis among community members attending social drinking venues in Lusaka, Zambia
Systematic testing for HIV and tuberculosis among community members attending social drinking venues in Lusaka, Zambia
Abstract
There is a high prevalence of unhealthy alcohol use (UAU) in sub-Saharan Africa, especially among persons living with HIV (PWH). Persons with UAU are at greater risk of HIV acquisition, while PWH with UAU are more likely to not know their HIV status, not be engaged in care, and experience poor outcomes. UAU also portends to a substantially higher risk of tuberculosis (TB) disease, regardless of HIV status.
-
PrEP Choice: Developing a PrEP decision support tool for young men who have sex with men
PrEP Choice: Developing a PrEP decision support tool for young men who have sex with men
Abstract
Young men who have sex with men (YMSM) are disproportionally affected by HIV in the United States, accounting for nearly half of new HIV diagnoses among MSM. Pre-exposure prophylaxis (PrEP) has demonstrated high levels of efficacy for HIV prevention; however, uptake has been suboptimal with uptake barriers including cost; stigma; not wanting to take a daily pill; and difficulty locating providers. New PrEP options are now available for YMSM and have the potential to address many of barriers to PrEP uptake, especially non-daily options which are preferred by many YMSM.
-
Inflammation, Aging, Microbes, Obstructive Lung Disease, and Diffusion Abnormalities (I AM OLD-DA): IDO Activity as a Driver of Lung Disease by Sex (IDOLS)
Inflammation, Aging, Microbes, Obstructive Lung Disease, and Diffusion Abnormalities (I AM OLD-DA): IDO Activity as a Driver of Lung Disease by Sex (IDOLS)
Abstract
Tuberculosis (TB) remains a major cause of morbidity and mortality for people living with HIV (PWH) worldwide, particularly in low-income settings. HIV and TB are both associated with increased rates of obstructive lung disease (OLD), with post-TB lung disease being an increasingly recognized entity associated with both pulmonary dysfunction and persistent respiratory symptoms. Sex-based differences have been found in TB prevalence, with men demonstrating higher rates of TB in multinational studies. However, whether there are sex-based differences in post-TB OLD among PWH is unknown.
-
Modulation of mTOR signaling using metformin during therapeutic SIV vaccination to achieve stringent post-treatment control
Modulation of mTOR signaling using metformin during therapeutic SIV vaccination to achieve stringent post-treatment control
Abstract
Most HIV-infected patients who stop taking antiretroviral drugs experience rapid viral rebound and suffer in the longer term from the presence of more virus in blood and lower CD4+ T cell counts. HIV-1 infection generally increases T-cell metabolism, which means that cells are more active, which promotes successful viral integration and replication. Our preliminary data show that although therapeutic T cell vaccination can effectively generate cytotoxic T cells that kill HIV-infected cells, in most cases this antiviral activity is insufficient to limit viral replication.
-
Antiretroviral Drug Penetration in HIV Reservoir Sites using Tissue from Deceased Donors
Antiretroviral Drug Penetration in HIV Reservoir Sites using Tissue from Deceased Donors
Abstract
Reduction of persistent HIV-infected cells in reservoir tissues is essential towards HIV cure. It is difficult to measure tissue penetration of therapeutics (antiretrovirals, ARVs, and curative agents) in many of these sites (e.g. brain, cardiac, lung tissue) due to the inability to sample these tissues in living people. Leveraging postmortem tissue banked at UCSF from deceased people with HIV (PWH), we will determine ARV penetration in these tissue reservoir sites, and determine if there is a link between ARV exposure to size the viral reservoir in each tissue.
-
HIV Cure via Direct Cytotoxic Depletion of the HIV Reservoir
HIV Cure via Direct Cytotoxic Depletion of the HIV Reservoir
Abstract
Combination antiretroviral therapy (cART) for the treatment of HIV infection has been a tremendous medical success, which continues to make strides.1 cART has dramatically reduced morbidity and mortality associated with HIV infection, allowing those that are infected to live for years without progressing to AIDS. cART does not clear the infection, however, and infected people must remain on treatment indefinitely. There have been several instances of HIV cure or remission.
-
Characterization and assessment of telomerase transduced primary CD4+ T-cells as a model to study HIV latency.
Characterization and assessment of telomerase transduced primary CD4+ T-cells as a model to study HIV latency.
Abstract
Although significant strides have been made in controlling viral pathogenicity via. Anti-Retroviral Therapy (ART), a major barrier to curing HIV-1 infection is the transcriptionally silent, latent proviral reservoir that resides within HIV infected individuals. These stable yet extremely rare (~1 in 1 million cells) viral reservoirs are primarily thought to be harbored in quiescent, homeo-statically proliferating, resting memory CD4+ T-cells.
-
A examination of the intersection between mobility and HIV outcomes among Black cisgender and transgender women in Atlanta
A examination of the intersection between mobility and HIV outcomes among Black cisgender and transgender women in Atlanta
Abstract
Progress towards ending the HIV epidemic among Black American women, particularly among those living in the American south, is severely delayed. Data from international studies suggest that mobile and migrant women may be an especially vulnerable and underserved group within an already marginalized population. Yet, to date, the HIV implications of migration and mobility among Black American women have yet to be explored, despite evidence of an historic internal migration of Black Americans to southern urban centers.
-
Identifying clinic factors that shape population health outcomes in times of crisis
Identifying clinic factors that shape population health outcomes in times of crisis
Abstract
Primary health care clinics in South Africa were confronting substantial population burdens of HIV and non-communicable disease (NCD) with limited resources even prior to the Covid-19 pandemic. Care outcomes and implementation of new programs vary between clinics in the same settings; qualitative research suggests that clinic factors such as leadership may play a key role in optimizing primary care.